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ASSESSING THE EFFECT OF BLOCKING CCL2-CCR2 SIGNALING
AXIS ON BREAST CANCER BRAIN METASTASIS
Yutao Qi, M.S.
Advisory professor: Dr. Dihua Yu, Ph.D., M.D.
Breast cancer brain metastases have remained one of the most intense challenges
for precision cancer therapeutics, but current treatment options are limited and not
curative. Recently, our lab reported that adoptive PTEN downregulation in metastatic
breast tumor cells activates PI3K/NF-ƙB signaling and increases the secretion of the
chemokine CCL2, which enhances the chemotaxis of CCR2+ myeloid cells, a major
subpopulation of bone marrow-derived myeloid cells (BMDMs), from peripheral blood
into the brain tumor microenvironment (TME), eventually promoting brain metastasis
outgrowth by driving immune suppression. Here, in this project we have been aiming
to develop effective therapies by immune-modulating the roles of the CCL2-CCR2
signaling axis in immune dysregulation in brain metastasis. We demonstrated that
CCR2 antagonism cannot sufficiently impede breast cancer brain metastasis in
multiple preclinical models, including two syngeneic immunocompetent models and a
CCR2-deficient model, although the CCR2 antagonist PF-04136309 significantly
blocks monocyte trafficking in blood and CCR2+ myeloid cell infiltration into the brain
TME. Our data provides great caution for targeting CCR2+ myeloid cells in the TME,
since blockade of the CCL2-CCR2 axis has been a popular area of interest in therapy
development for many other cancer types, suggesting the clinical outcome of CCR2
antagonists may be highly context-dependent. Moreover, we showed that CCL2
VI

upregulation promotes brain metastasis in the newly-established WHIM3 PDX TNBC
model, which sheds light on potential therapeutic opportunities of our targeting
elevated CCL2 secretion for brain metastasis patients. Overall, our findings provide a
new preclinical rationale for further exploration into the immune-modulation of the
CCL2-CCR2 signaling axis for cancer therapy development.
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Chapter 1. Background and Introduction
1.1. Breast cancer brain metastasis and current therapies
Breast cancer, one of the most leading causes of death for women at the global level,
arises primarily from the aberrant epithelial cells of the lobules or the mammary ducts
[1], which, along with lung cancer and melanoma, is a common solid tumor type to
develop brain metastasis [2-4]. Breast cancer brain metastasis occurs as a stage IV
advanced tumor, when metastatic tumor cells disseminate from their primary tumor
sites to brain - the most complex organ in the central nervous system (CNS) of human
body [5, 6]. Triple-negative breast cancer (TNBC), having neither estrogen receptor
(ER) nor progesterone receptor (PR) expression and little expression of human
epidermal growth factor receptor 2 (HER2/neu/erbB-2), accounts for approximately
10-15% of all breast cancer subtypes and develops brain metastases with the highest
incidence together with HER2-overexpressing (HER2+) subtype [7, 8].
In the United States, around 300,000 patients are newly diagnosed with breast cancer
every year, 5%-20% of which will develop symptomatic brain metastases with a 1year survival rate less than 20% [5, 6]. Moreover, the incidence of breast cancer brain
metastasis has been rising, especially when recent advances in targeted therapies
and immunotherapies have prolonged the overall survival (OS) of breast cancer
patients, which increases risk for them to develop brain metastasis [9, 10]. What is
even worse, those therapeutic drugs, efficacious in removing primary breast cancer
tumors, cannot effectively eradicate metastases in this CNS organ [9, 10], since they
aren’t able to pass through the blood-brain barrier (BBB). For instance, trastuzumab,
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a recombined anti-HER2 monoclonal antibody (mAb) in treating primary HER2+ breast
cancer patients, is ineffective in preventing the development of brain metastasis in
patients, due to the presence of BBB [11-13].
Generally, current treatment options for breast cancer brain metastasis patients are
very limited, and none of the available therapies, including conventional
radiotherapies and chemotherapies, is curative, which has emerged as an intense
challenge in the era of precision cancer therapeutics [14]. Therefore, the underlying
mechanisms of brain metastasis remain to be better elucidated in this field, and more
effective therapies are in urgent need for brain metastasis patients for prolonging their
progression-free survival (PFS) and improving their quality of life (QOL).
1.2. Brain tumor microenvironment and its contributions to brain metastasis
Due to the existence of BBB and shortage of the immune system, the brain had been
conventionally considered as an immunologically privileged organ [15-17]. More
recently, however, many immune cell types and various immune responses have
been characterized in brain under both normal and disordered conditions [17, 18].
There is now increasing evidence to suggest that brain tumor microenvironment
(TME) is constituted by its unique and complex network of the interactions between
tumor cells, astrocyte, microglia, brain endothelial cells, extracellular matrix (ECM), or
bone marrow-derived macrophages or myeloid cells (BMDMs) and other immune
cells, collectively contributing to the outgrowth of primary brain tumors or brain
metastases (Figure 1) [19-21]. Particularly, in experimental brain metastasis models,
two major myeloid subpopulations, CNS microglia (CCR2-/CX3CR1+) and BMDMs,
have been frequently observed [22-23]. Microglia, as tissue-resident macrophages,
-2-

possess immuno-stimulatory properties in maintaining brain homeostasis, while
during brain metastasis outgrowth they can also drive immune suppression through
[24, 25]. During the metastatic process, BMDMs are recruited from peripheral blood
into brain tumor microenvironment, which is involved in both antigen presentation and
brain metastasis progression. However, the exact roles of the intricate population of
BMDMs during breast cancer brain metastasis remains elusive [26-28].

Figure 1. Schematic diagram depicting brain tumor microenvironment. Major cell types
were described in brain tumor microenvironment, collectively contributing to the proliferation
and outgrowth of tumor cells. Reprinted with permission from Lorger M. “Tumor
microenvironment in the brain”. Cancers (Basel), 2012;4(1):218-43.

The association between tumor cells and tumor microenvironment (TME) was initially
explained by the “seed and soil” hypothesis proposed Stephen Paget, which has been
further developed by Isaiah Fidler and supports that cancer metastasis progression
results from the successful seeding of disseminated tumor cells into metastatic niches
– tumor microenvironment in distant organs [29]. Especially, when the BBB integrity is
compromised by the dissemination of primary breast cancer cells, a variety of immune
-3-

cells would be recruited into brain metastatic niches, including the infiltration of
peripheral BMDMs into the brain parenchyma [16, 27, 30].

Figure 2. Adoptive PTEN loss results in elevated CCL2 expression, facilitating the
outgrowth of brain metastasis in the brain TME. (a) Disseminated breast cancer cells are
extravasated from peripheral blood into the brain TME. (b) Astrocyte-derived exosomes are
secreted into TME. (c) Adoptive PTEN loss from secreted exosomes containing PTENtargeting microRNAs leads to the increased expression of chemokine CCL2 in tumor cells. (d)
Upregulated CCL2 secretion recruits more IBA1+/CCR2+ myeloid cells from peripheral blood
into the brain TME. (e) Recruitment of more IBA1+/CCR2+ myeloid cells drives immune
suppression in TME, enhances tumor cell proliferation and facilitates the outgrowth of breast
cancer brain metastasis. Reprinted with permission from Zhang L, Zhang S, Yao J, Lowery
FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M,
McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu
D. “Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis
outgrowth.” Nature 2015;527(7576):100-4.
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Figure 3. Effects of CCL2 knockdown in MDA-MB-231 TNBC model on brain metastasis.
(A) CCL2 knockdown prolongs mouse survival in MDA-MB-231 TNBC model. (B) IF staining
showed that CCL2 knockdown reduces IBA1+/CCR2+ myeloid cell infiltration. (C) Ki67 IHC
showed that CCL2 knockdown results in decreased proliferation of tumor cells. (D) TUNEL
assay showed that CCL2 knockdown leads to increased apoptosis of tumor cells. Reprinted
with permission from Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M,
Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J,
Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. “Microenvironment-induced
PTEN loss by exosomal microRNA primes brain metastasis outgrowth.” Nature
2015;527(7576):100-4.
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Our lab recently reported that brain TME-induced PTEN loss facilitates the outgrowth
of breast cancer brain metastasis (Figure 2). Mechanistically, astrocyte-derived
extracellular vehicles (EVs) (also called as exosomes), containing PTEN-targeting
microRNAs, lead to PTEN downregulation in metastatic tumor cells, which activates
NF-ƙB signaling and increases the secretion of chemokine CCL2 (also referred to as
monocyte chemoattractant protein-1, MCP-1) [30-32], a member of the CC chemokine
(or β-chemokine) subfamily. Then, upregulated CCL2 secretion enhances the
recruitment of CCL2 receptor-positive myeloid cells (CCR2+/CX3CR1low), a major
subpopulation of BMDMs, from peripheral blood into brain TME, eventually promoting
breast cancer brain metastasis outgrowth by driving immune suppression [19, 33-35].
Moreover, my colleagues discovered that CCL2 knockdown in an experimental brain
metastasis model (MDA-MB-231, a TNBC cell line) significantly prolongs mouse
survival (Figure 3A), and reduces IBA1+/CCR2+ myeloid cell recruitment from blood
and infiltration into the brain TME (Figure 3B). And CCL2 knockdown also results in
decreased proliferation (Figure 3C) and increased apoptosis (Figure 3D) of metastatic
tumor cells in mouse brain lesions [19].
Generally, our lab revealed a direct correlation between elevated CCL2 secretion,
IBA1+/CCR2+ myeloid cell infiltration and brain metastasis progression [19], and
further demonstrated that modulation of the brain TME would be a promising
therapeutic strategy for brain metastasis [36-38].
1.3. CCL2-CCR2 axis and its association with cancer metastasis
Chemokines are an extended subfamily of chemotactic cytokines in responsible for
driving the movement of various immune cells to cancer or inflammation-related
-6-

niches, which is usually described as chemotaxis. Interaction between the chemokine
CCL2 and its main receptor CCR2 plays a critical role in attracting various types of
immune cells, including myeloid and lymphoid cells, to the forming niches of
inflammation [39-41].

Figure 4. Roles of the CCL2-CCR2 signaling axis in attracting immune cells for
promoting cancer progression. (A) Crosstalk between tumor cells and immune cells
through the CCL2-CCR2 signaling axis within TME promotes cancer progression. Reprinted
with permission from Hao Q, Vadgama JV, Wang P. “CCL2/CCR2 signaling in cancer
pathogenesis.” Cell Commun Signal 2020;18 (1):82. (B) Flow cytometric analysis of PD-L1
expression in brain-infiltrating myeloid cells collected from metastatic lesions. (Work in Figure
4B was done by Dr. Lin Zhang)

Specifically, those CCL2-attracted immune cells, originating from hematopoietic stem
cells (HSC), are comprised of monocytes/tumor-associated macrophages (TAMs),
myeloid-derived suppressor cells (MDSCs, including M-MDSCs (monocytic) and
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PMN-MDSC (polymorphonucler/granulocytic)), dendritic cells (DCs), natural killer
(NK) cells and memory T cells, on which surfaces CCR2 has been reported to be
highly expressed (Figure 4A) [37-39, 42]. Particularly, accumulation of CCR2+ TAMs
and MDSCs into TME contributes to the initial formation of the pre-metastatic niches
in TME, results in immunosuppressive microenvironment and eventually facilitates
metastasis outgrowth [30, 38].
The CCL2-CCR2 signaling axis has been characterized in many cancer types and
inflammation-related diseases, and there is accumulating evidence that it is also
associated with cancer metastasis [30]. During cancer metastasis progression,
elevated CCL2 is primarily secreted by cancer cells, while the expression levels of
other CCR2’s chemokines, including CCL7 (also known as MCP-2), CCL8 (MCP-3)
and CCL13 (MCP-4), are very much lower (Figure 4A) [43]. Therefore, together with
our findings in breast cancer brain metastasis, pharmacological targeting of the CCL2CCR2 axis have been a hot area of interest for developing cancer therapies [45, 46].
So far, several selective antagonists targeting the CCL2-CCR2 axis, including CCR2
inhibitors (CCR2i) or anti-CCL2 antibodies, have been under clinical trials for
validating their safety, tolerability and efficacy on patients with cancer or inflammationrelated diseases [44, 45]. Particularly, PF-04136309, an orally administered and
small-molecule CCR2 antagonist in clinical development for treating patients with
advanced pancreatic adenocarcinoma [44], can efficiently antagonize CCR2-mediated
chemotaxis by preventing CCL2 binding on human CCR2+ myeloid cells in blood [44].
For instance, an ongoing clinical trial (NCT01413022) has showed from its phase I
study that PF-04136309 is safe and tolerable, and could, in combination with
-8-

FOLFIRINOX (consisting of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin)
regimen, effectively prevent the infiltration of tumor-associated CCR2+ myeloid cells
into metastatic niches and significantly restore anti-tumor immune responses [44].
Moreover, there is compelling evidence that tumor-associated BMDMs recruited from
blood, in which CCR2+ myeloid cells are its major subpopulation, can confer
resistance to anti-PD-1 monoclonal antibody (nivolumab) based immune checkpoint
blockade (ICB) therapies [42, 45, 46]. Consistently, our flow cytometric analysis
showed that PD-L1 (programmed death-ligand 1) is expressed in brain-infiltrating
myeloid cells within metastatic niches (Figure 4B), indicating that the recruited CCR2+
myeloid cells would mediate cytotoxic CD8 T-cell dysfunction and compromise the
efficacy of ICB immunotherapy for treating metastatic brain tumors [45]. Accordingly,
inhibiting the trafficking of CCR2+ myeloid cells to the brain TME with CCR2
antagonists may circumvent their therapeutic resistance to ICB treatment.
Therefore, in order to develop effective therapeutic options for treating patients with
stage IV breast cancer brain metastasis, we firstly proposed to evaluate the efficacy of
the CCR2 antagonist PF-04136309 alone, or the potential synergistic effect in
combination with anti-PD-1 immunotherapy on brain metastasis in immunocompetent
murine models.

-9-

Chapter 2. Hypothesis, Specific Aims and Significance
As discussed above, the primary goal of my thesis project is to develop effective
therapeutic strategies to impede breast cancer brain metastasis by immunemodulating the brain TME through the CCL2-CCR2 axis, which can be fast-track
translated into clinical trials for stage IV metastatic breast cancer patients in brain.
Mainly based on previous studies from our lab, we hypothesized that blocking CCR2+
myeloid cell infiltration into the brain TME with CCR2 antagonists (alone or combined
with ICB treatment), or alternatively neutralizing the upregulated CCL2 secretion with
anti-CCL2 mAb, can impede the outgrowth of breast cancer brain metastasis [47]. To
test this hypothesis, we proposed 3 specific aims:
Aim 1. Evaluate the efficacy of the CCR2 antagonist PF-04136309 alone, or
combined with ICB therapy, for treating breast cancer brain metastasis models
We aimed to evaluate whether PF-04136309, the CCR2 antagonist alone or in
combination with ICB immunotherapy, can reduce tumor myeloid cell infiltration into
the mouse brain TME of immunocompetent brain metastasis mouse models, including
4T1:BALB/c and EO771:C57BL/6J syngeneic models, effectively inhibit or reverse
outgrowth of brain metastasis, and significantly prolong mouse survival. Notably, the
effectiveness of PF-04136309 has not been assessed for patients with either primary
breast cancer or brain metastasis.
Aim 2. Target elevated CCL2 secretion for blocking CCR2+ myeloid cell trafficking in
a new TNBC PDX model to inhibit brain metastasis outgrowth
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As described above, our lab also reported more exciting findings about the CCL2CCR2 axis in brain metastasis. Particular, my colleagues discovered that nude mice
injected with CCL2-deleted MDA-MB-231 TNBC cells had a significantly longer
survival period, and experienced decreased CCR2+ myeloid cell infiltration into the
brain TME and reduced proliferation and increased apoptosis of tumor cells [19].
Therefore, especially when the desired objectives of Aim 1 could not be fully
achieved, we proposed to characterize the effects of the neutralization of the elevated
CCL2 secretion on brain metastasis by using a new patient-derived xenograft (PDX)
TNBC model - WHIM3, which was established by Dr. Helen Piwnica-Worms’ group at
UT MD Anderson cancer center [48]. Mechanistically, this proposed aim is not a
simple extension of our previous findings based on CCL2 knockdown, especially
considering the promiscuous interaction between CCL2 and its chemokine receptors
and the complicated heterogeneity with CCR2+ immune cells [49, 50].
Aim 3. Examine the roles of the CCL2-CCR2 axis in immune dysregulation in breast
cancer brain metastasis models
We have been aimed to examine the impact of gain of CCL2 function in the WHIM3
PDX TNBC model and loss of CCL2 function in an immunocompetent
EO771:C57BL/6J mouse model to determine CCL2’s functions in regulating immune
surveillance in tumorigenesis and brain metastasis outgrowth. Moreover, we planned
to compare the incidence and outgrowth of breast cancer brain metastasis in CCR2deficient (C57BL/6J background) mice with those in wild-type ones, which would
further enable us to uncover the regulatory mechanisms by the CCL2-CCR2 signaling
axis in immune dysregulation in breast cancer brain metastasis.
- 11 -

Generally, our proposed studies would establish a preclinical basis to advance the
validated immune-modulating therapy options toward human clinical trials for treating
patients with metastatic breast cancer in brain, and provide deeper insights into the
roles of the CCL2-CCR2 signaling axis in immune dysregulation and pathophysiology
of breast cancer brain metastasis.
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Chapter 3. Materials and Methods
3.1. Cell culture
Mouse TNBC cell lines (4T1 and E0771) were ordered from the American Type
Culture Collection (ATCC). WHIM3 PDX TNBC model was provided from Dr. Helen
Piwnica-Worms (UT MD Anderson Cancer Center, MDACC). All cell lines were
verified by the UT MDACC Cell Line Characterization Core Facility. Br3 cells were
established as brain-seeking sublines after 3 rounds of in vivo selection as previously
described [19]. All the cells were grown in two-dimensional (2D) culture in Dulbecco’s
Modified Eagle Medium (DMEM/Ham's F-12, 1:1 mixture, Caisson Labs, Cat #:
D6421-500ML) with 10% (v/v) fetal bovine serum (FBS, HyClone, Cat #:
SH30071.03HI) and 1% (v/v) penicillin-streptomycin (100x, Gibco, Cat #: 10378016),
and kept in a 37 °C humidified with 5% CO2. All cell lines or tumor models were tested
negative about mycoplasma contamination.
3.2. Antibodies and reagents
Table 1. Antibodies for staining or western blot

Antibody

Host

Reactivity

Source

Catalog N.O.

IHC: anti-IBA1

rabbit

mouse, human, rat

Wako

019-19741

IHC: anti-Ki67

rabbit

human, mouse

Abcam

ab15580

WB: anti-CCL2

mouse

human, mouse

Invitrogen

MA5-17040

WB: anti-β-actin

mouse

mouse, human, rat

Sigma

A5441

2nd Ab anti-Mouse

/

mouse

GE

NA931
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Table 2. Antibodies for flow cytometry

Antibody-Dye

Host

Reactivity

Source

Catalog N.O

CD11b-BV510 (M1/70)

rat

mouse

Biolegend

101263

Gr1-PE/Cy7 (RB6-8C5)

rat

mouse

Biolegend

108416

Gr1-PE (RB6-8C5)

rat

mouse

Biolegend

108407

Ly6G-Alexa-Fluor647 (1A8)

rat

mouse

Biolegend

127610

Ly6C-FITC (H.K1.4)

rat

mouse

Biolegend

128005

F4/80-PE (BM8)

rat

mouse

Biolegend

123110

CD8/PerCP-Cy5.5 (53-6.7)

rat

mouse

Biolegend

100734

CD4/PE (GK1.5)

rat

mouse

Biolegend

100408

CD45-APC-eFluor780 (30-F11)

rat

mouse

eBioscience

47-0451-82

Viability Dye eFluor450

/

/

eBioscience

65-0863-14

PD-L1-PE/Cy7 (10E.9G2)

rat

mouse

Biolegend

124314

CCR2-FITC

rabbit

mouse

Novus

NBP1-48338F

Antibodies used for staining, western blot (WB) and flow cytometry in this project were
listed in Table 1 and Table 2.
3.3. Plasmid construction for CCL2 overexpression
Mouse CCL2 cDNA comprising 447 bp flanked with NheI (NEB, Cat #: R3131) and
Xhol (NEB, Cat #: R0146L) restriction enzyme sites, was amplified with high-fidelity
PCR (KAPA HiFiTM, KAPA Biosystems, Cat #: KK2801). The sense and anti-sense
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primers were 5’-CTAGATGCTAGCATGCAGGTCCCTGTCATGCTTCTG-3’ and 5’CTAGATCTCGAGCTAGTTCACTGTCACACTGGTCACTC-3’, respectively. The PCR
amplification product was purified with a gel extraction kit (QIAGEN, Cat #: 28706),
which was then double-digested and ligated into pLenti-GIII-CMV2 vector (ABM).
After being transformation into Stbl3 competent cells (Invitrogen, Cat #: C7373-03),
bacterial cells were under Kanamycin selection with LB-Agar plates. Single E. coli
colonies were picked and amplified in LB medium. Amplified plasmid DNA was
purified with QIAprep Spin Miniprep Kit (QiIAGEN, Cat #: 27104). The constructed
plasmids were validated by both plasmid restriction digestion and Sanger sequencing
at the sequencing core of UT MD Anderson Cancer Center.
3.4. Plasmid construction for CCL2 CRISPR/Cas9 knockout
To knockout CCL2 in EO771.Br3 cells, lentiCRISPRv2 one-vector plasmid from
Addgene were used following the published protocol [51, 52]. The lentiviral CRISPR
plasmid was digested with BsmBI (Fermentas, Cat #: FD0454) and then purified with
QIAquick gel extraction kit (QIAGEN, Cat #: 28706). Two single-guide RNAs
(sgRNAs) targeting CCL2 were designed and selected with an online design tool
(https://www.synthego.com/crispr-grna/design-tool): sgRNA1: 5’GCTGGTGAATGAGTAGCAGC-3’; sgRNA2: 5’-GCAAGATGATCCCAATGAGT-3’.
These two sgRNAs and their complementary stands were synthesized by IDT
Biotech. Each pair of DNA oligos were phosphorylated with T4 Polynucleotide Kinase
(PNK) (NEB, Cat #: M0201S) and gradually annealed. The resulting oligo duplex was
ligated into BsmBI-digested lentiCRISPRv2 vector with Quick Ligase (NEB, Cat #:
M2200S), and ligation products were transformed into Stbl3 competent cells
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(Invitrogen, Cat #: C7373-03). After transformation, bacterial cells were under
Ampicillin selection with LB-Agar plates. Single bacterial colonies were picked and
amplified in LB medium. Amplified plasmid DNA was purified with QIAprep Spin
Miniprep Kit (QiIAGEN, Cat #: 27104). Constructed plasmids were verified by DNA
sequencing at the sequencing core of UT MD Anderson Cancer Center.
3.5. Generation of stable cell lines
To overexpress CCL2 in WHIM3.Br3 cells or knockout CCL2 in EO771.Br3 cells,
lentivirus was firstly produced with the above constructed plasmids. Their lentiviral
plasmids were transfected into the 293T cell line with lipofectamine 3000 reagent
(Thermo Fisher, Cat #: L3000008), which were pre-incubated with the psPAX2
packaging plasmid and the pMD2G envelope plasmid. After 48 h transfection,
produced lentiviruses were harvested, centrifuged and filtered for incubating with their
target cells with the addition of 10 μg/mL polybrene (Sigma-Aldrich, Cat #: TR-1003G) for 24 h for infection. After infection, the cells were grown for another 48h and then
selected in the presence of puromycin (2 μg/ml, Thermo Fisher, Cat #: A1113802) as
a selection markers. The generated stable cell lines or clones were eventually verified
by western blot for detecting CCL2 expression.
3.6. Western blotting
Western blotting (WB) was performed evaluating CCL2 expression. Cell pellets were
resuspended with our super lysis buffer (1.7 M urea, 3.3% SDS). Resuspended cells
or cell lysates were then sonicated and centrifuged. Total protein concentration of
each cell lysate was quantified with the Pierce BCA (bicinchoninic acid) Protein Assay
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Kit (Thermo Fisher, Cat #: A53225). Equal amount of each cell lysate (20 ug) were
mixed with protein-loading buffer, separated with SDS-PAGE (sodium dodecyl sulfatepolyacrylamide gel electrophoresis) and then transferred to nitrocellulose (NC)
membranes (0.45 μm) (Bio-Rad, Cat #: 1620112). The resulting protein-transferred
NC membranes were blocked with 5% milk in phosphate-buffered saline with 0.05%
tween 20 (PBS-T) for 15 min and then incubated overnight (> 8 h) with primary
antibody (e.g. anti-CCL2 Ab and anti-β-actin Ab) (Table 1) at 4 °C cold room. The
resulting membranes were washed for three times with PBS-T and then subjected to
be incubated with HRP (Horseradish peroxidase)-linked secondary antibodies (Table
1) for 1 h, and chemiluminescent signals were quantitatively detected with the
PierceTM ECL (enhanced chemiluminescence) Western Blotting Substrate (Thermo
Scientific, Cat #: 32109).
3.7. Immunohistochemistry staining and TUNEL staining
Tissues processing, embedding and sectioning for fixed mouse brain were done at
Histology Core at UT MD Anderson Cancer Center. Tissue section slides were
sequentially subjected to de-paraffinization, rehydration, antigen retrieval (0.01 M
citrate pH 6.0, 95 °C, 30 min) and endogenous peroxidase blocking with 3% H2O2 (15
min). After blocking with serum (Protein Block Serum-Free, Dako, Cat #: X0909),
tissue slides were incubated with primary antibodies (anti-CCL2 Ab and anti-β-actin
Ab, Table 1) at 4 °C overnight (> 8 h). On the next day, HRP color development was
performed for tissue slides with DAB chromogen (Dako, Cat #: K3468) and then
counterstained with hematoxylin. Quantification of positive IBA1 and Ki67 IHC staining
in mouse brain lesions were measured as percentage of positively-stained cells per
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field (5 fields per tissue lesion), which was normalized by the total brain tumor cell
number in each imaging field.
TUNEL assay performed similarly with immunohistochemistry (IHC) staining, in which
the in situ cell death (apoptosis) detection kit (Promega, Cat #: G3250) was used.
Similarly, positively-stained apoptotic cells was quantified as average for each field (5
random fields per tissue sample).
Table 3. Primers for RT-qPCR

Cytokine/Chemokine

Primers
Fw: 5’-GCTACAAGAGGATCACCAGCAG-3’

CCL2
Rv: 5’-GTCTGGACCCATTCCTTCTTGG-3’
Fw: 5’-CCTGCTGCTTTGCCTACCTCTC-3’
CCL5
Rv: 5’-ACACACTTGGCGGTTCCTTCGA-3’
Fw: 5’-ATGCCTGTCACGTTGAATGAAG-3’
GM-CSF (CSF2)
Rv: 5’-GCGGGTCTGCACACATGTTAG-3’
Fw: 5’-ATCCCGAAGGCTTCCCTGAGTG-3’
G-CSF (CSF3)
Rv: 5’-AGGAGACCTTGGTAGAGGCAGA-3’
Fw: 5’-TCCAGAGCTTGAAGGTGTTGCC-3’
CXCL1
Rv: 5’-AACCAAGGGAGCTTCAGGGTCA-3’
Fw: 5’-TACCACTTCACAAGTCGGAGGC-3’
IL-6
Rv: 5’-CTGCAAGTGCATCATCGTTGTTC-3’
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3.8. Quantitative reverse-transcription polymerase chain reaction (RT-qPCR)
All the brain-seeking cell lines of mouse breast cancer in Yu lab was firstly solved in
TRIzol reagent (Thermo Fisher, Cat #: 15596026). Total RNA was extracted with the
RNeasy Mini Kit (QIAGEN, Cat #: 74104). For each sample, 1 μg RNA was reversely
transcribed to cDNA with the iScriptTM cDNA Synthesis Kit (Bio-Rad, Cat #: 1708891),
equal volume (1 μl) of produced cDNA was used as templates for qPCR with iQTM
SYBR® Green Supermix (Bio-Rad, Cat #: 1708880) on CFX Connect Real-Time PCR
System (Bio-Rad). RT-qPCR primers for six cytokines or chemokines (CCL2, CCL5,
CXCL1, GM-CSF, G-CSF and IL-6) were selected and synthesized by IDT biotech
(Table 3). Quantification of relative mRNA expression was calculated with the 2-ΔΔCt
method after logarithmic transformation, which was normalized to 18S expression as
the internal control.
3.9. Mouse cytokine array analysis
Cytokine secretion from 4T1.Br3 and EO771.Br cell lines was detected with Mouse
Cytokine Array Panel A (R&D Systems, Cat #: ARY006). After 48-hour cell growth,
cell culture supernatant was harvested and centrifuged to remove particulates. Each
of the two samples was diluted, mixed with a detection cocktail containing 40
biotinylated antibodies, and then incubated with a NC membrane at 4 °C overnight (>
8 h). Chemiluminescence signals were quantitatively measured with the PierceTM
ECL Western Blotting Substrate (Thermo Scientific, Cat #: 32109) and exposed for 110 minutes. Quantification of mean pixel density for each membrane image was
analyzed with Image J, which was normalized to three references.
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3.10. Flow cytometry
Around 100 μl fresh blood was taken from the heart from each mouse and collected
into BD Microtainers® blood collection tubes (BD Biosciences). Blood samples were
subjected to centrifugation to separate upper serum layer. Lower layer of blood
samples were resuspended with RBC (red blood cell) lysis buffer (155 mM NH4Cl, 10
mM KHCO3, 0.1mM EDTA pH8.0) to remove RBCs. If necessary, RBC lysis was
repeated. After two washes with sorting buffer (0.5% BSA (bovine serum albumin) in
PBS), white blood cells (WBCs) are incubated with myeloid or lymphoid cell antibody
markers (Table 2) for 30 minutes at 4 °C, and then analyzed with a BD FACSCanto II
cytometer (BD Biosciences). Quantification of each type of WBCs was analyzed by
using FlowJo threshold gating.
BV2 cells were firstly washed three times with sorting buffer (0.5% BSA in PBS) and
incubated for 1 h at 4 °C with either anti-CCR2-FITC or control IgG. After three
washes, stained cells were quantitatively analyzed with a BD FACSCanto II cytometer
(BD Biosciences).
3.11. MTT cell proliferation assay
Measurement of tumor cell (4T1.Br3 and WHIM3.Br3) proliferation was based on the
assay of the incorporation of non-radioactive 3-(4, 5-dimethylthiazolyl-2)-2, 5diphenyltetrazolium bromide (MTT) into cellular DNA. Before trypsinization for MTT
assay, tumor cells should be under good condition. For each cell type, 3 x 10 3 tumor
cells were seeded into each well of the 96-well tissue-culture plates (Corning®
Costar®, Cat #: CLS3595) in triplicate with 100 μl cell culture medium. Every 24 h at
- 20 -

the same time point, 50 μl of 5 mg/ml MTT in PBS (pH 7.5) was added directly into the
100 μl culture medium in each well and incubated at 37 °C for 2 h, until the fastestgrowing cells reached 90% confluency. The cell culture supernatant was then
carefully removed without disturbing the attached cells, and 100 μl DMSO was added
into each well of the 96-well plates for thoroughly solubilizing the MTT-labeled DNA.
Absorbance was measured at 570 nm and 620 nm with a microplate reader (BioTek
Instruments), which was normalized to the first-day measurement.
3.12. Transwell migration assay
Transwell migration assay was carried out as described previously [19]. 1 x 105 BV2
cells under good status were collected in serum-free media and seeded inside each of
the transwell permeable supports (Corning® Costar, 3 μm pore size, Cat #: 3415) in
biological replicates for each condition. DMEM (without serum) was added both inside
and outside the transwell chambers. Outside the transwell chambers of 24-well
transwell plates, either BSA control or CCL2 (20 ng/ml) was added in serum-free
DMEM media. Inside the transwell chambers, the CCR2 antagonist PF-04136309 with
various concentrations (1 μM and 10 μM) was added in serum-free media [53]. After
20 h incubation, inside media was firstly aspirated, and non-migrated cells on the
upper side of transwell membranes were carefully removed with cotton swabs (Qtips). Migrated BV2 cells on the bottom side of transwell membranes were subjected
to be fixed with 10% buffered formalin for 1 h, stained with 0.5% crystal violet for 15
minutes and then visualized after three washes. Quantification of the migrated BV2
cells was determined from bright-field images in three representative fields for each
transwell membrane and normalized to that under BSA control condition.
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3.13. In vivo mouse experiments
All mouse procedures and experimental protocols in this project were conducted in
accordance with approvals from the Institutional Animal Care and Use Committee
(IACUC) at UT MD Anderson Cancer Center. All the mice involved in this project were
purchased from the Jackson Laboratory: BALB/c mice (Stock No: 000651), C57BL/6J
mice (B6, Stock No: 000664), CCR2-deficient C57BL/6J mice (B6.129(Cg)Ccr2tm2.1Ifc/J, Stock No: 017586 | CCR2RFP), and Nude mice (NU/J, Stock No:
002019).
For the 4T1:BALB/c immunocompetent brain metastasis model, 2 x 10 3 cells were
intracranially injected in each of the 60 randomly-grouped female mice (8 weeks old,
15 mice in each of the 4 groups). At Day 5 after injection, different treatment was
started for each of the grouped mice: vehicle (100 μl, 30% PEG300 + 3% TWEEN-80
+ 67%PBS) + IgG (100 μl, 200 μg/mouse), CCR2i (100 μl, 100 mg/kg) + IgG, vehicle
+ anti-PD-1 Ab (100 μl, 200 μg/mouse) and CCR2i + anti-PD-1 Ab. CCR2 or vehicle
was administered twice daily via oral gavage, while anti-PD-1 Ab or IgG was given
every 3 days via intraperitoneal (i.p.) injection. Mice were sacrificed for detailed
analysis at indicated times in Figure 7, and mouse tissues, including blood, brains,
lungs and spleens, were harvested. The tumor volumes of mouse brain lesions were
calculated: 1/2 x length x width2.
For the EO771: C57BL/6J immunocompetent brain metastasis model, 1 x 103 cells
were intracranially injected in each of the 15 randomly-grouped female mice (8 weeks
old, 7 or 8 mice in each of the 2 groups). At Day 0 immediately after injection,
treatment was started: vehicle (100 μl, 30% PEG300 + 3% TWEEN-80 + 67%PBS)
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and CCR2i (100 μl, 100 mg/kg). CCR2 or vehicle was administered twice daily via oral
gavage. All 15 mice were euthanized at Day 19 for detailed analysis, when the first
mouse nearly died.
For evaluating the impact of loss of CCR2 on the incidence and outgrowth of breast
cancer brain metastasis, 3 x 104 EO771 cells were injected via intracarotid artery
(ICA) into each of the CCR2-deficient (6 mice) or wild-type (WT) (8 mice) mice.
Simultaneously, 1 x 105 EO771 cells were orthotopically injected into the mammary
fat pad (MFP) of each of the 14 mice. All 14 mice were sacrificed at Day 20 for
detailed analysis, when the first mouse was very weak. MFP tumors were also
harvested for analysis, and tumor sizes were also measured.
For evaluating the impact of CCL2 overexpression on the incidence and outgrowth of
brain metastasis, 1 x 105 WHIM3.Br3 cells (control (8 mice) or CCL2-overexpression
(9 mice)) were injected via ICA injection for each of the 17 mice. For measuring brain
metastasis progression, bioluminescence imaging (BLI) for luciferase reporter assay
was weekly taken for totally 12 weeks, which intensities were normalized to that on
Day 1 after injection. The remaining mice in this experiment are now being grown for
survival analysis.
For the ongoing in vivo study for evaluating the efficacy of CCL2-neutralizing antibody
for treating the WHIM3 PDX TNBC brain metastasis model, 1.2 x 105 WHIM3.Br3
cells were injected via ICA injection for each of the 23 randomly-grouped mice (2
groups, IgG (12 mice) vs anti-CCL2 Ab (11 mice)). On Day 11 after injection,
treatment was started: IgG and anti-CCL2 Ab (10 μg/mouse for each i.p. injection).
This experiment will last 5 more weeks, when all the mice will be sacrificed for
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detailed analysis. Mouse tissues, including blood, brains, lungs and spleens, will be
harvested for evaluating the efficacy of anti-CCL2 Ab. Three sets of brain-infiltrating
immune cells will be collected for mass cytometry (CyTOF) analysis.
3.14. Statistical and survival analyses
Statistical analyses about all the quantitative experiments in this project were
performed with GraphPad Prism 8 (GraphPad). All the statistics was represented as
mean ± s.e.m. (standard error of mean), t-test, at least 3 technical replicates for each
experiment, and the levels of all statistical significance shown in the figures of this
thesis were analyzed and expressed as P values (calculated probabilities): *, P <
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; N.S., not significant. Survival
curves are being generated by the Kaplan-Meier method and log-rank test.
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Chapter 4. Results
4.1. In vitro pilot assays demonstrated the potential specificity and efficiency of
CCR2 antagonist on CCR2+ myeloid cells
Before the in vivo studies for evaluating the efficacy of our proposed therapeutic
strategies in Aim 1, I conducted two in vitro pilot assays with the CCR2 antagonist PF04136309, which enabled verifying its potential specificity and effectiveness on
CCR2+ myeloid cells.
4.1.1. CCR2 antagonist has an insignificant effect on tumor cell proliferation

Figure 5. Effect of the CCR2 antagonist PF-04136309 on cancer cell proliferation. Two of
our major cell lines, 4T1.Br3 (A) and WHIM3.Br3 (B), with the concentrations of PF-04136309
ranging from 0 to 50 μM. Statistics is represented as mean ± s.e.m., t-test, 3 technical
replicates for each experiment; N.S., not significant.

To test whether the CCR2 antagonist PF-04136309 have any effect on cancer cell
proliferation, we performed MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide) assay with two of our major cell lines: 4T1.Br3 (Figure 5A) and WHIM3.Br3
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(Figure 5B) (after 3 rounds of in vivo selection, Br3 cells are common brain-seeking
sublines developed in Yu lab). With up to 50 μM PF-04136309 added into growth
medium, which is much higher than clinically relevant concentrations (~8 μM) [53],
this CCR2 antagonist has no clear effect on tumor cell proliferation for either 4T1.Br3
or WHIM3.Br3 cell lines, although both of them have a low level of CCR2 expression
[54]. This in vivo cancer cell proliferation assay suggested that PF-04136309 may
specifically influence the trafficking of CCR2+ myeloid cells.
4.1.2. CCR2 antagonist efficiently inhibits the directional cell migration of BV2

Figure 6. CCR2 antagonist can efficiently inhibit the directional cell migration of BV2
towards CCL2 chemoattraction. (A) Flow cytometric analysis of BV2 cells for CCR2
expression with either IgG or anti-CCR2 antibody. (B) Transwell migration assay for verifying
whether the CCR2 antagonist PF-04136309 can inhibit the directional cell migration of BV2
towards CCL2. Either CCL2 or BSA was added into serum-free media outside transwells. (C)
Quantification of migration assay under various concentrations of CCR2 antagonist. Statistics
is represented as mean ± s.e.m., t-test, triplicates per experiment; **, P < 0.01; ***, P < 0.001;
****, P < 0.0001.
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To verify the effectiveness of the CCR2 antagonist PF-04136309, I carried out
transwell migration assay with BV cells (microglial cell line), which have high CCR2
expression from flow cytometry (Figure 6A). Compared with controls, the addition of
10 μM PF-04136309, which is close to its clinically relevant concentration [53], could
efficiently inhibit the directional migration of CCR2+ BV2 cells towards CCL2
chemoattraction (Figure 6B & 6C). Collectively, these data from the two in vitro pilot
assays necessitated us starting our treatment strategies for brain metastasis models.
4.2. Multiple preclinical models revealed that CCR2 antagonism can’t
sufficiently impede breast cancer brain metastasis
4.2.1. Evaluate the efficacy of CCR2 antagonist alone, or combined with immune
checkpoint blockade, in 4T1:BALB/c immunocompetent model
To evaluate the efficacy of the CCR2 antagonist (CCR2i) alone, or combined with ICB
(αPD-1 Ab), in an immunocompetent model, we intracranially injected 4T1 cells (2,000
cells) into each of the 60 BALB/c mice for mimicking established (late-stage) brain
metastasis, and started our 4 treatment strategies for this aggressive brain metastasis
model on Day 5: vehicle + IgG, CCR2i only, αPD-1 only and CCR2i + αPD-1. On Day
17 when the first mouse nearly died, 5 mice from each of the 4 treatment groups were
collected for more detailed analysis (Figure 7A). From H&E staining, no significant
differences were observed in brain lesion size between control and treated mice
(Figure 7B).However, Ki67 IHC staining revealed remarkably decreased proliferation
of tumor cells in treated mouse lesions (Figure 7C). Flow cytometric analysis of Ly6C+
cells in peripheral blood showed monocyte trafficking was blocked in CCR2i-treated
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mice (Figure 7D), and IBA1 IHC analysis indicated infiltration of CCR2+ myeloid cells
was decreased (Figure 7E).

Figure 7. Efficacy of CCR2 antagonist alone, or combined ICB, in 4T1:BALB/c
immunocompetent model. (A) Schematic representation of cancer model establishment and
treatment schedules. (B) Brain lesion volumes (tumor volume = length × width2 × 0.5) were
calculated from H&E staining. (C) Ki67 IHC staining analysis showing the proliferation
changes of tumor cells. (D) Flow cytometric analysis of Ly6C+ cells in peripheral blood. (E)
IBA1 IHC staining analysis showing infiltration of CCR2+ myeloid cells. Statistics is
represented as mean ± s.e.m., t-test; P values: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P
< 0.0001; N.S., not significant. (Work in Figure 7A was done in collaboration with Dr. Lin
Zhang and Ping Li.)
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4.2.2. Identification of a more suitable model for targeting CCR2+ myeloid cells

Figure 8. Identification of a more suitable tumor model for targeting CCR2+ myeloid
cells. (A) qPCR showing cytokine expression among our major mouse breast cancer brain
metastasis models: 4T1.Br3, EO771.Br, 2208L.Br, T11 and EMT6. (B) Cytokine array
analysis with cell culture supernatant from both 4T1.Br3 and EO771.Br. Statistics in panel (A)
is represented as mean ± s.e.m., t-test, 3 technical replicates for each experiment; P values
between 4T1.Br3 and EO771.Br: ***, P < 0.001; ****, P < 0.0001.

To clarify why our treatment objectives were not fully achieved with 4T1:BALB/c
model, we made a screen among our breast cancer brain seeking cell lines in Yu lab
for a more suitable model for targeting CCR2+ myeloid cells, since one possible
reason is that mice bearing 4T1 tumors were reported to have significant increases in
both Ly6C+ monocytes and Ly6G+ neutrophils in peripheral blood. Firstly, we
performed RT-qPCR (reverse transcription quantitative polymerase chain reaction) for
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checking cytokine expression with mRNA extracted from our major mouse brain
metastasis models: 4T1.Br3, EO771.Br, 2208L.Br, T11 and EMT6 (Figure 8A).
Specifically, while 4T1.Br3 cells have high expression in CCL2, GM-CSF, G-CSF and
CXCL1 for stimulating and recruiting both granulocyte and monocyte, EO771.Br cells
highly express CCL2 and CCL5 chemokines, which are mainly responsible for
recruiting monocytes from blood. These data indicated that the EO771.Br cell line
may be a better model for targeting CCR2+ myeloid cells.
To verify our above findings with RT-qPCR, we further employed cytokine array
analysis with cell culture supernatant from both 4T1.Br3 and EO771.Br, which
enabled detecting the relative levels of as many as 40 mouse cytokine secretion
(Figure 8B). Consistently, compared with the 4T1.Br3 cell line, EO771.Br cells secret
similar levels of CCL2 and CCL5 but much lower G-CSF and CXCL1 into blood
(Figure 8C). Cumulatively, these results further suggested the EO771.Br breast
cancer brain metastasis model should be selected for evaluating the efficacy of the
CCR2 antagonist PF-04136309 in the immunocompetent model.
4.2.3. Validate the effectiveness of CCR2 antagonist in EO771 syngeneic model
To evaluate the efficacy of the CCR2 antagonist (CCR2i) PF-04136309 alone in a
smaller-scale in the EO771.Br syngeneic model, we intracranially injected 1k EO771
cells into each of the 15 C57BL/6J mice, and started our treatment for this aggressive
late-stage brain metastasis model on Day 0. On Day 19 when the first mouse nearly
died, all 15 mice in the two divided groups were collected for detailed analysis (Figure
9A). From H&E staining results, no significant differences were found again in brain
lesion size between control and CCR2i-treated mice (Figure 9B).
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Figure 9. Efficacy of CCR2 antagonist in EO771.Br:C57BL/6J immunocompetent model.
(A) Schematic representation of cancer model establishment and treatment design in a small
scale. (B) Mouse brain lesion sizes (brain tumor volume = length × width2 × 0.5) were
recorded from their H&E staining sections. (C) Hematology showing the concentration of
monocytes in peripheral blood. (D) Ki67 IHC staining showing the proliferation changes of
tumor cells in mouse brain lesions after CCR2i treatment. (E) TUNEL assay analysis showing
tumor cell apoptosis in mouse brain lesions. (F) IBA1 IHC staining analysis showing the
infiltration of CCR2+ myeloid cells into mouse brain lesions. (G) IBA1 IHC staining shown in a
low magnitude for a general IBA1+ cell distribution around mouse brain lesions after treatment
with the CCR2 antagonist. Statistics is represented as mean ± s.e.m., t-test; P values: ***, P <
0.001; ****, P < 0.0001; N.S., not significant. (Work in Figure 9A was done in collaboration
with Dr. Lin Zhang.)
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Nevertheless, we found once again that monocyte trafficking was significantly blocked
in peripheral blood of CCR2i-treated mice (Figure 9C). Moreover, Ki67 IHC staining
and TUNEL staining analyses showed remarkably decreased proliferation and
increased apoptosis of cancer cells in CCR2i-treated mouse brain lesions,
respectively (Figure 9D & 9E). Consistently with the blocked recruitment of monocytes
in blood, IBA1 IHC staining analysis indicated that infiltration of CCR2+ myeloid cells
was decreased in the CCR2i-treated mouse brain lesions (Figure 9F).
Strikingly, IBA1+/CCR2+ myeloid cells were mainly distributed on the edge regions of
CCR2i-treated mouse brain lesions from IBA1 IHC staining (Figure 9G). Collectively,
these observations indicated that the CCR2 antagonist PF-04136309 could not only
cross the brain BBB, but also efficiently block the infiltration of CCR2+ myeloid cells
into mouse brain lesions.
4.2.4. Determine the impact of loss of CCR2 on the incidence and outgrowth of
breast cancer brain metastasis
As described previously (Figure 4B), CCR2+ cells are a major subpopulation of braininfiltrated myeloid cells isolated from brain metastasis lesions. To further explore the
roles of the CCR2+ myeloid cells in breast cancer brain metastasis, we injected 30k
EO771.Br via ICA (intracarotid artery) into each of CCR2-deficient (CCR2-/-) or control
wild-type (WT) C57BL/6 (B6) mice to generate brain metastasis models (Figure 10A).
Because of extravasation of brain-seeking (Br) cells into the brain parenchyma, the
ICA injection was applied for mimicking earlier-stage of brain metastasis. On Day 20
when the first mouse nearly died, all the mice were collected for detailed analysis as
described previously. Consistent with the data derived from CCR2i treatment, no
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significant differences in brain lesion size were observed between control and CCR2deficient mice (Figure 10B). Similarly, Ki67 IHC staining also revealed proliferation of
tumor cells was decreased in CCR2-deficient mouse lesions (Figure 10C). Moreover,
the trafficking Ly6C+ myeloid cells in peripheral blood was completely blocked in
CCR2-deficient mice (Figure 10D), and the infiltration of CCR2+ myeloid cells was
decreased into CCR2-deficient mouse brain lesions (Figure 10E).

Figure 10. Impact of loss of CCR2 on the incidence and outgrowth of breast cancer
brain metastasis. (A) Schematic representation of generating brain metastasis models. (B)
Brain lesion volumes (brain lesion volume = length × width2 × 0.5) were calculated from H&E
staining results. (C) Ki67 IHC staining showing tumor cell proliferation status in mouse brain
lesions. (D) Flow cytometric analysis of Ly6C+ cell changes in peripheral blood. (E) IBA1 IHC
staining showing infiltration of CCR2+ myeloid cells in brain lesions. Statistics is represented
as mean ± s.e.m., t-test; P values: *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; N.S., not
significant. (Work in Figure 10A was done in collaboration with Dr. Lin Zhang and Dr. Yimin
Duan.)
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In summary, with multiple preclinical models, we demonstrated that CCR2
antagonism is not sufficient for impeding breast cancer brain metastasis, although it
can efficiently blocked the infiltration of CCR2+ myeloid cells into brain lesions.

Figure 11. Possible reasons for the insufficiency of CCR2 antagonism in brain
metastasis models. (A) Relative expression of CCL2-binding receptors in normal brain cells.
(B) MFP tumor sizes (tumor volume = length × width2 × 0.5) were measured with a caliper
and then calculated. Statistics is represented as mean ± s.e.m., t-test; P values: ***, P <
0.001.

There are two possible reasons for the insufficiency of CCR2 antagonism in breast
cancer brain metastasis models. One is that CCR2 antagonism cannot efficiently
block the infiltration of microglial cells into brain lesions, which also leads to
immunosuppression in brain TME, since microglia has low CCR2 but high CCR1 and
CCR5 expression, which can also interact with CCL2 (Figure 11A) [49]. The other is
that a population of CCR2+ monocytes, DCs or natural killer (NK) cells were reported
as immune effectors with anti-metastatic roles [50], which blockade may bring
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undesired effects to brain metastasis models. This point can also explain why CCR2deficient mice bearing EO771 cells have significantly bigger tumors in primary MFP
(mammary fad pad) (Figure 11B).

Figure 12. Impact of CCL2 overexpression in a PDX model on the incidence and
outgrowth of breast cancer brain metastasis. (A) Western blot showing the CCL2
expression levels among WT, control and CCL2-overexpressed PDX WHIM3.Br3 cells, which
can also stably express luciferase. (B) Schematic representation of establishing brain
metastasis models with ICA injection (100k cells per injection) of either control (8 mice) or
CCL2-overexpressed WHIM3 cells (9 mice) into nude mice. (C) Quantification of
bioluminescence imaging photon changes after 1 min exposure, which measurement was
normalized to the total intensity on Day 1 after ICA injection. (D) Representative BLI images
of mice from the two groups, which were taken every week. Statistics is represented as mean
± s.e.m., t-test; P values: *, P < 0.05. (Work in Figure 12B was done in collaboration with Dr.
Lin Zhang and Dr. Yimin Duan.)
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4.3. Target upregulated CCL2 secretion in the WHIM3 PDX TNBC brain
metastasis model
Towards the above two possible reasons for the insufficiency of CCR2 antagonism in
brain metastasis, our alternative strategy to target upregulated CCL2 has become
essential to block the infiltration of immunosuppressive myeloid cells. Our targeting
CCL2 upregulation were proposed to be performed in the newly-established PDX
TNBC model - WHIM3 [48]. Before evaluating the efficacy of a CCL2-neutralizing
antibody (αCCL2 Ab) based therapeutic intervention, we firstly planned to validate the
impact of CCL2 overexpression in the WHIM3 PDX model on the incidence and
outgrowth of brain metastasis.
4.3.1. Examine the impact of CCL2 overexpression in the PDX model on the
incidence and outgrowth of breast cancer brain metastasis
To examine the effect of CCL2 overexpression in the PDX model on the incidence
and outgrowth of metastatic breast cancer in brain, we generated CCL2overexpressed (CCL2 OE) WHIM3.Br3 cells (Figure 12A), and then started an in vivo
study with ICA injection of either control (ctrl) or WHIM3.Br3 CCL2 OE cells into nude
mice (Figure 12B). Whole-body bioluminescence imaging (BLI) was taken every week
to measure the progression of mouse brain metastasis (Figure 12C & 12D).
Remarkably, mice injected with WHIM3.Br3 CCL2 OE cells showed enhanced brain
metastasis outgrowth, compared to those injected with control cells (Figure 12C). This
in vivo study is still ongoing, and we will see if CCL2 overexpression will lead to
shorter mouse survival.
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Generally, these in vivo results indicated that CCL2 upregulation in breast cancer
cells promotes brain metastasis in the newly-established PDX model, which is
consistent with the effect of CCL2 knockdown in MDA-MB-231 cell line (Figure 3) [19],
suggesting it is necessary to validate the efficacy of CCL2-neutralizing antibody
(αCCL2 mAb) in this PDX TNBC brain metastasis model.
4.3.2. Assess the efficacy of CCL2-neutralizing antibody based therapeutic
intervention for the PDX TNBC brain metastasis model

Figure 13. Efficacy of CCL2-neutralizing antibody based therapeutic intervention for the
WHIM3 PDX TNBC brain metastasis model. (A) Schematic representation of establishing
brain metastasis models via ICA injection (120k cells per injection) with WHIM3.Br3 cells and
treatment plan with either IgG control or CCL2-neutralizing Ab. (B) Quantification of weekly
bioluminescence imaging photon changes after 1 min exposure, which measurement was
normalized to the total intensity on Day 1 after ICA injection. (Work in Figure 13A was done in
collaboration with Dr. Lin Zhang and Dr. Yimin Duan.)
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To evaluate the therapeutic efficacy of CCL2-neutralizing antibody on the incidence
and outgrowth of brain metastasis, we have started an in vivo study with ICA injection
of WHIM3 cells into nude mice, which will last around 5 more weeks (Figure 13A).
This in vivo mouse experiment is of special clinical significance, since WHIM3 is a
newly-developed PDX TNBC brain metastasis model (48). Mouse whole-body BLI is
being taken every week to track whether the CCL2-neutralizing antibody can
efficiently block the progression of mouse brain metastasis (Figure 13B).
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Chapter 5. Discussion and Future Directions
In this project, our primary goal is to assess the outcomes of blocking CCR2+ myeloid
cell infiltration on breast cancer brain metastasis and to develop effective therapy
regimens for brain metastasis patients by immune-modulating the CCL2-CCR2
signaling axis. Taken together, with multiple brain metastasis mouse models, we have
demonstrated that CCR2 antagonism cannot sufficiently impede the outgrowth of
brain metastasis, which reveals considerably functional heterogeneity within the
CCR2+ myeloid cell population [55, 56]. Thus, our findings provide a new preclinical
rationale for further exploration into the CCL2-CCR2 axis for cancer therapy. Notably,
consistent with a more bimodal distribution in brain lesion size in CCR2i-treated
mouse groups, around 20-35% of treated mice were even clearly weaker than control
ones (Figure 7B & 9B), suggesting severe side effects from the simple CCR2
antagonism. And when targeting the CCL2-CCR2 signaling axis, great caution needs
to be considered for drug administration, since blockade of this signaling axis has
been a popular area of interest and many pharmaceutical companies and research
groups have already reported that CCR2 antagonists are efficacious in several other
cancer types [45, 46, 49, 50].
By contrast, our targeting elevated CCL2 secretion may circumvent the “two possible
problems” from CCR2 antagonism (Figure 11), which may be a promising treatment
strategy to be translated for patients with breast cancer brain metastasis, although it
was an only alternative in the beginning. Specifically, neutralization of the upregulated
CCL2 expression from cancer cells may reduce the infiltration of microglial cells into
the brain TME, since CCR1 and CCR5, which are also CCL2 receptors, are highly
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expressed on the surface of microglia (Figure 11A) [49]. Moreover, our ongoing CCL2
neutralization may bring less perturbation to CCR2+ immune effector cells, since the
CCL2-CCR2 axis doesn’t necessarily play a major role in driving their chemotaxis to
sites of inflammation. For instance, the CCL4/5-CCR5 axis mainly contributes to the
recruitment of conventional dendritic cells (cDCs) in antitumor immunity [57]. Besides,
the fact that neutralization of CCL2 secretion can block tumor angiogenesis among
endothelial cells has signified broader necessity for our targeting CCL2 for brain
metastasis (58).
Consistent with our analyses, there has been extensive evidence that bone marrowderived tumor-infiltrating myeloid cells (BMDMs) in tumor microenvironment are
substantially heterogeneous, including immune-suppressive and immune-stimulatory
subpopulations. However, lack of knowledge about the phenotypic and functional
heterogeneity within BMDMs has hampered the development of their targeted
therapies [59, 60]. Hence, further in-depth investigation about the heterogeneity is
essential for translational research, and the ideal therapy regimen should require the
combination of the blockade of immune-suppressive myeloid cells with the induction
of immune-stimulatory ones.
Accordingly, in order to develop effective therapeutic options toward human clinical
trials for treating brain metastasis patients and gain deeper insights into the intricate
roles of the CCL2-CCR2 signaling axis in immune dysregulation and pathophysiology
of breast cancer brain metastasis, we will pursue the following directions for future
investigations in this project:
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Complete the ongoing evaluation of the efficacy of CCL2-neutralizing
antibody based therapeutic intervention for treating the WHIM3 PDX TNBC
brain metastasis model;



Dissect the heterogeneity within infiltrated myeloid cells in metastatic brain
tumors with flow cytometry/Mass cytometry (CyTOF) to confirm the
existence of CCR2+ immune effector cells [61, 62];



Determine the impact of loss of CCL2 function on breast cancer brain
metastasis in an immunocompetent mouse model (CCL2-KO
EO771:C57BL/6J model), and evaluate the efficacy of a CCL2-neutralizing
antibody for treating the EO771:C57BL/6J syngeneic immunocompetent
preclinical model;

What’s more, one long-term goal related with this project is to delve deeply into the
mechanisms regulating both pro-tumor and anti-tumor effects of CCR2+ cells and
better utilize the dual roles of the CCL2-CCR2 signaling axis in both early tumor
immune surveillance and cancer metastasis progression [49, 63]. For instance,
although CCR2+ myeloid cells were mainly reported to be involved in promoting tumor
progression and metastasis [49, 63], an anti-metastatic/cytotoxic role for CCR2+
monocytes has been revealed in the lung metastasis microenvironment, when murine
breast cancer cell line 4T1 was orthotopically transplanted into its syngeneic
immunocompetent BALB/c mice [50]. Therefore, a systematic study about various
breast cancer models with varying injection routes may enable us to elucidate the
underlying regulatory mechanism controlling this highly context-dependent signaling
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axis, from which anti-metastatic roles of CCR2+ immune effector cells can be
enhanced for developing novel immunotherapies.
Additionally, microglia, central nervous system-resident myeloid cells, was reported to
suppress CD4+/CD8+ T cell activation and proliferation, drive immunosuppression in
the brain TME and promote brain metastasis outgrowth [56]. Hence, characterizing
the specific roles of each subgroup of the general myeloid population and the possible
cooperativity between microglia and BMDMs in fostering immunosuppressive niches
may benefit the future development of cancer immunotherapies.
In summary, this work highlights the insufficiency of CCR2 antagonism in breast
cancer brain metastasis and provides great caution for targeting CCR2+ myeloid cells
in the TME for other cancer types, suggesting the clinical outcome of CCR2
antagonists may be highly context-dependent. And our targeting the elevated CCL2
secretion in a new PDX preclinical model sheds light on potential therapeutic
opportunities for brain metastasis patients.
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